(OTCBB: MIVT)
(FRANKFURT: MIV), a leading developer of next-generation coatings and
advanced drug delivery systems for cardiovascular stents and other
implantable medical devices, today...
MIV Therapeutics, Inc. (OTCBB: MIVT)
(FRANKFURT: MIV), a leading developer of next-generation coatings and
advanced drug delivery systems for cardiovascular stents and other
...
MIV Therapeutics, Inc. (OTCBB: MIVT) (FRANKFURT: MIV), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable...
ATLANTA, Oct. 23, 2007 (PRIME NEWSWIRE) -- MIV Therapeutics, Inc. (OTCBB:MIVT) (Frankfurt:MIV), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular...
Company Presence at TCT to Include One Oral Presentation and Two Posters
MIV Therapeutics, Inc. (OTCBB: MIVT)
(FRANKFURT: MIV), a leading developer of next-generation coatings and
...
#83: MIVT News MIV Therapeutics Executes Private Financings for $4 Million to Support Acquisitions, Development and Distribution of Next Generation Stents
ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT)
(FWB:MIV), a leading developer of next-generation biocompatible
polymer-free drug-eluting stents and advanced drug...
#82: MIVT News Investrend Affiliate SISM Research 'Morning Note' Reiterates MIV Therapeutics 'Buy/4' Rating, $2.50 Target Valuation, Citing Plans To Introduce New Products In Key Global Markets Next Quarter
NEW YORK--(BUSINESS WIRE)--(Investrend Research Syndicate) Ernest C. Schlotter, a senior analyst
with Investrend affiliate SISM Research and a four star analyst
according to StarMine,...
ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT)
(FWB:MIV), a leading developer of next-generation biocompatible
polymer-free drug-eluting stents and advanced drug...
ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB: MIVT) (FWB: MIV), a leading developer of
next-generation biocompatible polymer-free drug-eluting stents and
advanced drug...
#79: MIVT News MIV Therapeutics 'Buy/4' Rating, $2.50 Target Valuation Reiterated In Research Note By Investrend Affiliate SISM Research, Indicating Greater Market Potential And Citing Recent Superior Performance of Stent Coating Technologies In Recent Tests
NEW YORK--(BUSINESS WIRE)--(Investrend Research Syndicate) Ernest C. Schlotter, a senior analyst
with Investrend affiliate SISM Research and a four star analyst
according to StarMine,...
ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT)
(FWB:MIV), a leading developer of next-generation biocompatible
polymer-free drug-eluting stents and advanced drug...
#77: MIVT News MIV Therapeutics Releases New Corporate Video Presentation on Company's Programs to Develop Advanced HAp-Based Drug-Eluting Cardiovascular Stents
ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT)
(FWB:MIV), a leading developer of next-generation biocompatible
drug-eluting stents, has released a new corporate video in...
ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT)
(FWB:MIV), a leading developer of next-generation biocompatible
drug-eluting stents, announced today that it intends to...
ATLANTA--(BUSINESS WIRE)--MIV Therapeutics (OTCBB:MIVT)
(FWB:MIV), announced that Dr. Greg Kaluza, Scientific Director, Center
for Research in Cardiovascular Interventions at The...
ATLANTA--(BUSINESS WIRE)--Sept. 21, 2006--MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for...
